Welcome to the latest edition of Fenwick’s Securities Law Update. This issue contains updates and important reminders on the following topics...more
As life sciences companies expand internationally, regulatory readiness must evolve into a strategic capability that supports global business planning and innovation....more
On December 18, 2025, President Trump signed into law the National Defense Authorization Act (The “NDAA”). Among its provisions, the NDAA includes an updated version of the BIOSECURE Act (the “Act”)....more
Signaling a major shift in U.S. policy on biotechnology supply chain security, Congress has enacted the BIOSECURE Act as part of the Fiscal Year 2026 National Defense Authorization Act (NDAA), The Act imposes broad...more
On December 18, the BIOSECURE Act became law as Sec. 851 of the National Defense Authorization Act (NDAA) for Fiscal Year 2026. The BIOSECURE Act will prohibit the U.S. government from contracting with any company that uses...more
On Thursday, December 18, the President signed the National Defense Authorization Act (NDAA) for Fiscal Year 2026. The NDAA contains several new national security regulatory controls, including a new Section 851 “Prohibition...more
Key Takeaways- The BIOSECURE Act, now part of NDAA, will put in motion government-wide restrictions on “biotechnology companies of concern” and eventually bar agencies from procuring their biotech equipment or services....more
The BIOSECURE Act, which restricts the ability of U.S. executive agencies to contract with “Biotechnology Companies of Concern,” is now law. First introduced in the 2023-2024 legislative session and nearly passed into law...more
Key Takeaways : House advances BIOSECURE Act as part of NDAA legislation. The latest version would bar contractors and federal funding recipients from using certain biotechnology equipment or services linked to foreign...more
The final draft of the FY 2026 National Defense Authorization Act (NDAA) includes the proposed BIOSECURE Act (the Act), which would place restrictions on dealings with certain “biotechnology companies of concern” (BCOCs) by...more
On Dec. 10, 2025, the House of Representatives passed a compromise version of the fiscal year 2026 National Defense Authorization Act (NDAA), by a vote of 312 to 112. ...more
On Sunday, December 7, 2025, Congress released the final draft compromise version of the FY 2026 National Defense Authorization Act (NDAA), and the package includes the BIOSECURE Act, reflecting weeks of additional...more
On October 9, the U.S. Senate adopted amendment 3841, adding Section 881, Prohibition on Contracting with Certain Biotechnology Providers, a version of the BIOSECURE Act, to its version of the FY 2026 National Defense...more